5-Fluorouracil and dihydropyrimidine dehydrogenase

International Journal of Clinical Oncology

Volumn 8, Issue 3, 2003, Pages 127-131

  Kubota, Tetsuro ^a  

^a KEIO UNIVERSITY   (Japan)

Author keywords

5 Fluorouracil; Dihydropyrimidine dehydrogenase (DPD); DPD inhibitory fluoropyrimidines (DIFs)

Indexed keywords

5 ETHYNYLURACIL; CAPECITABINE; CISPLATIN; DIHYDROPYRIMIDINE DEHYDROGENASE; DOXIFLURIDINE; FLUOROPYRIMIDINE DERIVATIVE; FLUOROURACIL; FOLINIC ACID; GIMERACIL; MITOMYCIN C; MITOXANTRONE; OROTATE PHOSPHORIBOSYLTRANSFERASE; OSTACIL; RIBONUCLEOTIDE REDUCTASE; TEGAFUR; THYMIDINE KINASE; THYMIDINE PHOSPHORYLASE; UFT; UNCLASSIFIED DRUG; URIDINE KINASE; URIDINE PHOSPHORYLASE;

ANEMIA; BONE MARROW SUPPRESSION; BRAIN DISEASE; BREAST CANCER; COLITIS; COLON CANCER; DERMATITIS; DIARRHEA; DRUG DEGRADATION; DRUG ELIMINATION; DRUG HALF LIFE; ENZYME DEFICIENCY; GENE MUTATION; GRANULOCYTOPENIA; HAND FOOT SYNDROME; HEAD AND NECK CANCER; HUMAN; KIDNEY DISEASE; LEUKOPENIA; LIVER CELL CARCINOMA; LIVER DYSFUNCTION; MUCOSA INFLAMMATION; NAUSEA; NEUROTOXICITY; NEUTROPENIA; ORTHOSTATIC HYPOTENSION; PANCREAS CANCER; PRIORITY JOURNAL; REVIEW; SEIZURE; SKIN CANCER; STOMACH CANCER; STOMATITIS; SYNCOPE; THROMBOCYTOPENIA; UTERINE CERVIX CANCER; VOMITING;

ANTIMETABOLITES, ANTINEOPLASTIC; DIHYDROURACIL DEHYDROGENASE (NADP); FLUOROURACIL; HUMANS; NEOPLASMS; OXIDOREDUCTASES; SENSITIVITY AND SPECIFICITY; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0041804297     PISSN: 13419625     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10147-003-0319-7     Document Type: Review

References (58)

1. Heidelberger C, Chaudhuri NK, Danenberg P, et al (1957) Fluorinated pyrimidines, a new class of tumor-inhibitory compounds. Nature 179:663-666
2. Liu G, Franssen E, Fitch MI, et al (1997) Patient preference for oral versus intravenous palliative chemotherapy. J Clin Oncol 15:110-115
3. Sobrero A, Kerr D, Glimelinus B, et al (2000) New directions in the treatment of colorectal cancer: a look to the future. Eur J Cancer 36:559-565
4. Diasio RB (1999) Clinical implications of dihydropyrimidine dehydrogenase inhibition. Oncology 13(suppl 3):17-21
5. Hoff PM, Pazdur R (1999) Dihydropyrimidine dehydrogenase inhibitory fluoropyrimidines: a novel class of oral antineoplastic agents. Semin Oncol 26(suppl 18):52-56
6. Diasio RB, Harris BE (1989) Clinical pharmacology of 5-fluorouracil. Clin Pharmacokinet 16:215-237
7. Naguib FNM, el Kouni MH, Cha S (1985) Enzymes of uracil catabolism in normal and neoplastic human tissues. Cancer Res 45:5405-5412
8. Ho DH, Townsend L, Luna MA, et al (1986) Distribution and inhibition of dihydrouracil dehydrogenase activities in human tissues using 5-fluorouracil as a substrate. Anticancer Res 6:781-784
9. Aboagye EO, Saleem A, Cunningham VJ, et al (2001) Extraction of 5-fluorouracil by tumor and liver: a noninvasive positron emission tomography study of patients with gastrointestinal cancer. Cancer Res 61:4937-4941
10. Chazal M, Etienne MC, Renee N, et al (1996) Link between dihydropyrimidine dehydrogenase activity in peripheral blood mononuclear cells and liver. Clin Cancer Res 2:507-510
11. Fleming RA, Milano G, Thyss A, et al (1992) Correlation between dihydropyrimidine dehydrogenase activity in peripheral mononuclear cells and systemic clearance of fluorouracil in cancer patients. Cancer Res 52:2899-2902
12. Etienne MC, Chatelut E, Pivot X, et al (1998) Co-variables influencing 5-fluorouracil clearance during continuous venous infusion: a NONMEM analysis. Eur J Cancer 34:92-97
13. Harris BE, Song R, Soong SJ, et al (1990) Relationship between dihydropyrimidine dehydrogenase activity and plasma 5-fluorouracil levels with evidence for circadian variation of enzyme activity and plasma drug levels in cancer patients receiving 5-fluorouracil by protracted continuous infusion. Cancer Res 50:197-201
14. Grem JL, Yee LK, Venzon DJ, et al (1997) Inter and intraindividual variation in dihydropyrimidine dehydrogenase activity in peripheral blood mononuclear cells. Cancer Chemother Pharmacol 40:117-125
15. Van Kuilenburg ABP, Van Lenthe H, Tromp A, et al (2000) Pitfalls in the diagnosis of patients with a partial dihydropyrimidine dehydrogenase deficiency. Clin Chem 46:9-17
16. Tuchman M, Stoeckeler JS, Kiang DT, et al (1985) Familial pyrimidinemia and pyrimidinuria associated with severe fluorouracil toxicity. N Engl J Med 313:245-249
17. Yokota H, Fernandez-Salguero P, Furuya H, et al (1994) cDNA cloning and chromosome mapping of human dihydropyrimidine dehydrogenase, an enzyme associated with 5-fluorouracil toxicity and congenital thymine uraciluria. J Biol Chem 269:23192-23196
18. Dobritzsh D, Schneider G, Schnackerz KD, et al (2001) Crystal structure of dihydropyrimidine dehydrogenase, a major determinant of the pharmacokinetics of the anti-cancer drug 5-fluorouracil. EMBO J 20:650-660
19. Raida M, Schwabe W, Haulser P, et al (2001) Prevalance of a common point mutation in the dihydropyrimidine dehydrogenase (DPD) gene within the 5′-splice donor site of intron 14 in patients with severe 5-fluorouracil (5-FU)-related toxicity compared with controls. Clin Cancer Res 7:2832-2839
20. Collie-Duguid ESR, Etienne MC, Milano G, et al (2000) Known variant DPYD alleles do not explain DPD deficiency in cancer patients. Pharmacogenetics 10:217-223
21. Collie-Duguid ESR, Johnston SJ, Powrie RH, et al (2000) Cloning and initial characterization of the human DPYD gene promoter. Biochem Biophys Res Commun 271:28-35
22. Shestopal SA, Johnson MR, Diasio RB (2000) Molecular cloning and characteraization of the human dihydropyrimidine dehydrogenase promoter. Biochim Biophys Acta 1494:162-169
23. Milano G, McLeod HL (2000) Can dihydropyrimidine dehydrogenase impact 5-fluorouracil-based treatment? Eur J Cancer 36:37-42
24. Kouwaki M, Hamajima N, Sumi S, et al (1998) Identification of novel mutations in the dihydropyrimidine dehydrogenase gene in a Japanese patient with 5-fluorouracil toxicity. Clin Cancer Res 4:2999-3004
25. Inada T, Jotsuka T, Matsuda G, et al (1999) Severe 5-fluorouracil-related toxicity in a Japanese patient with dihydropyrimidine dehydrogenase deficiency. Int J Clin Oncol 4:54-56
26. Okada R, Shibutani M, Matsuo T, et al (1990) Experimental neurotoxicity of 5-fluorouracil and its derivatives is due to poisoning the monofluorinated organic metabolites, monofluoroacetic acid and α-fluoro-β-alanine. Acta Neuropathol (Berl) 81:66-73
27. Arellano M, Malet-Martino M, Martino R, et al (1998) The anticancer drug 5-fluorouracil is metabolized by the isolated perfused rat liver and in rats into highly toxic fluoroacetate. Br J Cancer 77:79-86
28. Douillard JY, Hoff PM, Skillings JR, et al (2002) Multicenter phase III study of uracil/tegafur and oral leucovorin versus fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 20:3605-3616
29. Carmichael J, Popiela T, Radstone D, et al (2002) Randomized comparative study of tegafur/uracil and oral leucovorin versus parenteral fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 20:3617-3627
30. Hoff PM, Ansari R, Batist G, et al (2001) Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study. J Clin Oncol 19:2282-2292
31. Van Cutsem E, Twelves C, Cassidy J, et al (2001) Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study. J Clin Oncol 19:4097-4106
32. Yamamoto J, Haruno A, Yoshimura Y, et al (1984) Effect of coadministration of uracil on the toxicity of tegafur. J Pharm Sci 73:212-214
33. 19F magnetic resonance spectroscopy and chromatography. Jpn J Cancer Res 83:387-391
34. Davis ST, Joyner SS, Baccanari DP, et al (1994) 5-Ethynyluracil (776C85): protection from 5-fluorouracil-induced neurotoxicity in dogs. Biochem Pharmacol 48:233-236
35. Arellano M, Malet-Martino M, Martino R, et al (1997) 5-Ethynyluracil (GW776): effects on the formation of the toxic catabolites of 5-fluorouracil, fluoroacetate and fluorohydroxy-propionic acid, in the isolated perfused rat liver model. Br J Cancer 76:1170-1180
36. Johnston PG, Lenz HJ, Leichman CG, et al (1995) Thymidylate synthase gene and protein expression correlate and are associated with response to 5-fluorouracil in human colorectal and gastric tumors. Cancer Res 55:1407-1412
37. Lenz HJ, Leichman CG, Danenberg KD, et al (1996) Thymidylate synthase mRNA level in adenocarcinoma of the stomach: a predictor for primary tumor response and overall survival. J Clin Oncol 14:176-182
38. Leichman CG, Lenz HJ, Leichman L, et al (1997) Quantitation of intratumoral thymidylate synthase expression predicts for disseminated colorectal cancer response and resistance to protracted-infusion fluorouracil and weekly leucovorin. J Clin Oncol 15:3223-3229
39. Beck A, Etienne MC, Cheradame S, et al (1994) A role of dihydropyrimidine dehydrogenase and thymidylate synthase in tumor sensitivity to fluorouracil. Eur J Cancer 30A:1517-1522
40. Ishikawa Y, Kubota T, Otani Y, et al (1999) Dihydropyrimidine dehydrogenase activity and messenger RNA level may be related to the antitumor effect of 5-fluorouracil on human tumor xenografts in nude mice. Clin Cancer Res 5:883-889
41. Ishikawa Y, Kubota T, Otani Y, et al (2000) Dihydropyrimidine dehydrogenase and messenger RNA levels in gastric cancer: possible predictor for sensitivity to 5-fluorouracil. Jpn J Cancer Res 91:105-112
42. Scherf U, Ross DT, Waltham M, et al (2000) A gene expression database for the molecular pharmacology of cancer. Nat Genet 24:236-244
43. Grem JL, Danenberg KD, Behan K, et al (2001) Thymidine kinase, thymidylate synthase, and dihydropyrimidine dehydrogenase profiles of cell lines of the National Cancer Institute's anticancer drug screen. Clin Cancer Res 7:999-1009
44. Terashima M, Irinoda T, Fujiwara H, et al (2002) Role of thymidylate synthase and dihydropyrimidine dehydrogenase in tumor progression and sensitivity to 5-fluorouracil in human gastric cancer. Anticancer Res 22:761-768
45. Etienne MC, Cheradame S, Fischel JL, et al (1995) Response to fluorouracil therapy in cancer patients: the role of tumoral dihydropyrimidine dehydrogenase activity. J Clin Oncol 13:1663-1670
46. Salonga D, Danenberg KD, Johnson M, et al (2000) Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase. Clin Cancer Res 6:1322-1327
47. Horiguchi J, Takei H, Koibuchi Y, et al (2002) Prognostic significance of dihydropyrimidine dehydrogenase expression in breast cancer. Br J Cancer 86:222-225
48. Shirota Y, Ichikawa W, Uetake H, et al (2002) Intratumoral dihydropyrimidine dehydrogenase messenger RNA level reflects tumor progression in human colorectal cancer. Ann Surg Oncol 9:599-603
49. McLeod HL, Sludden J, Murray GI, et al (1998) Characterization of dihydropyrimidine dehydrogenase in human colorectal tumors. Br J Cancer 77:461-465
50. Jonston SJ, Ridge SA, Cassidy J, et al (1999) Regulation of dihydropyrimidine dehydrogenase in colorectal cancer. Clin Cancer Res 5:2556-2570
51. Uetake H, Ichikawa W, Takechi T, et al (1999) Relationship between intratumoral dihydropyrimidine dehydrogenase activity and gene expression in human colorectal cancer. Clin Cancer Res 5:2836-2839
52. Guimabaud R, Guichard S, Dusseau C, et al (2000) Dihydropyrimidine dehydrogenase activity in nomal, inflammatory and tumor tissues of colon and liver in humans. Cancer Chemother Pharmacol 45:477-482
53. Ho DH, Pazdur R, Covington W, et al (1998) Comparison of 5-fluorouracil pharmacokinetics in patients receiving continuous 5-fluorouracil infusion and oral uracil plus N1-(2′-tetrahydrofuryl)-5-fluorouracil. Clin Cancer Res 4:2085-2088
54. Baker SD, Khor SP, Adjei AA, et al (1996) Pharmacokinetic, oral bioavailability, and safety study of fluorouracil in patients treated with 776C85, an inactivator of dihydropyrimidine dehydrogenase. J Clin Oncol 14:3085-3096
55. Takechi T, Uchida J, Fujioka A, et al (1997) Enhancing 5-fluorouracil cytotoxicity by inhibiting dihydropyrimidine dehydrogenase activity with uracil in human tumor cells. Int J Oncol 11:1041-1044
56. Ahmed FY, Johnston SJ, Cassidy J, et al (1999) Eniluracil treatment completely inactivates dihydropyrimidine dehydrogenase in colorectal tumors. J Clin Oncol 17:2439-2445
57. Sallem A, Yap J, Osman S, et al (2000) Modulation of fluorouracil tissue pharmacokinetics by eniluracil: in-vivo imaging of drug action. Lancet 355:2125-2131
58. Takechi T, Fujioka A, Matsushima E, et al (2002) Enhancement of the antitumor activity of 5-fluorouracil (5-FU) by inhibiting dihydropyrimidine dehydrogenase activity (DPD) using 5-chloro-2,4-dihydroxypyridine (CDHP) in human tumor cells. Eur J Cancer 38:1271-1277